AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33827495 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC) followed by nine sessions of MOVE-I
Number of subjects: 137
Study 33827495 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (14 sessions of individual manual-based cognitive behavioral therapy and motivational interviewing (MOVE-I))
Number of subjects: 137
Study 33827495 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the trial
Number of subjects: 137
Study 35550827 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline family communication quality
Number of subjects: 147
Study 35550827 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment aimed at improving family communication
Number of subjects: 147
Study 34147142 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (800 mg loading dose on day 0 followed by 400 mg daily on days 1-9)
Number of subjects: 400
Study 34147142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 34147142 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 400
Study 35984380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Salbutamol (5 mg) with Magnesium Sulphate (95 mg)
Number of subjects: 90
Study 35984380 — intervention group
Group type: COMPARATOR
Intervention: Nebulized Salbutamol (5 mg) alone
Number of subjects: 90
Study 34965881 — intervention group
Group type: COMPARATOR
Intervention: Implementation program for shared decision-making (SDM) including training for HCPs, individual coaching for physicians, patient activation intervention, patient information material/decision aids, revision of quality management documents, and reflection on multidisciplinary team meetings (MDTMs).
Number of subjects: 2128
Study 34965881 — intervention group
Group type: COMPARATOR
Intervention: Implementation program for shared decision-making (SDM).
Number of subjects: 2128
Study 32310850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary prourokinase
Number of subjects: 260
Study 32310850 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 260
Study 32598812 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin followed by warfarin (1 mg/kg every 12 hours for 7 days, then warfarin to maintain INR 2.0-3.0)
Number of subjects: 42
Study 32598812 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban monotherapy (15 mg twice/day for 21 days, then 20 mg/day)
Number of subjects: 42
Study 34962672 — intervention group
Group type: EXPERIMENTAL
Intervention: 930 mg choline/d
Number of subjects: 20
Study 34962672 — intervention group
Group type: COMPARATOR
Intervention: 480 mg choline/d
Number of subjects: 20
Study 32372290 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10/25 mg
Number of subjects: 14919
Study 36235736 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 3 × 400 mg per day for 4 weeks
Number of subjects: 14
Study 36235736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 34030705 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC + vitamin A alone
Number of subjects: 0
Study 34030705 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC + vitamin A + zinc
Number of subjects: 0
Study 34030705 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC + vitamin A + Plumpy’Doz™
Number of subjects: 0
Study 32386077 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised Consumer Medicine Information (CMI) with usual care
Number of subjects: 140
Study 32386077 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 140
Study 34332269 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality rehabilitation system (VRRS)
Number of subjects: 30
Study 34332269 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive rehabilitation
Number of subjects: 30
Study 34009905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Cycle Deliberate Practice (RCDP)
Number of subjects: 24
Study 34254405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicemine (BHV-5500) 1.0 mg/ml (100 mg)
Number of subjects: 24
Study 34254405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 24
Study 32088427 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person weight loss group
Number of subjects: 150
Study 32088427 — intervention group
Group type: EXPERIMENTAL
Intervention: Video conference weight loss group
Number of subjects: 150
Study 32088427 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care weight loss group
Number of subjects: 150
Study 32088427 — intervention group
Group type: COMPARATOR
Intervention: No attendance
Number of subjects: 150
Study 35727762 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundation Residency Program
Number of subjects: 33
Study 33421648 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Mindful Self-Compassion training (8-week program via videoconferencing)
Number of subjects: 0
Study 33421648 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment waitlist control group
Number of subjects: 0
Study 34762373 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with basic treatment
Number of subjects: 60
Study 34762373 — intervention group
Group type: COMPARATOR
Intervention: Conventional basic treatment (control group)
Number of subjects: 60
Study 36333364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% hyaluronic acid (HA)
Number of subjects: 438
Study 36333364 — intervention group
Group type: COMPARATOR
Intervention: 0.05% cyclosporine A (CsA)
Number of subjects: 438
Study 36333364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% hyaluronic acid (HA) plus 0.05% cyclosporine A (CsA)
Number of subjects: 438
Study 36333364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine A (CsA) plus 0.5% carboxymethylcellulose (CMC)
Number of subjects: 438
Study 35162706 — intervention group
Group type: COMPARATOR
Intervention: Zumba (ZG)
Number of subjects: 107
Study 35162706 — intervention group
Group type: COMPARATOR
Intervention: Football (FG)
Number of subjects: 107
Study 35232805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab administered subcutaneously every 8 weeks
Number of subjects: 4480
Study 32600327 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-min chewing trial
Number of subjects: 31
Study 32600327 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min chewing trial
Number of subjects: 31
Study 32600327 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 40-min and 60-min chewing trials
Number of subjects: 31
Study 32600327 — intervention group
Group type: COMPARATOR
Intervention: Comparison between sexes
Number of subjects: 31
Study 33724101 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational cognitive behavioral therapy fatigue management group
Number of subjects: 200
Study 33724101 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 35435089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive and resistive electric transfer (CRET) therapy for 15 minutes on lower back
Number of subjects: 30
Study 35435089 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy for 15 minutes on lower back
Number of subjects: 30
Study 34408741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DE111®
Number of subjects: 11
Study 33402278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiron™ sirolimus‐eluting stent (SES)
Number of subjects: 170
Study 33402278 — intervention group
Group type: COMPARATOR
Intervention: Biomatrix™ Flex biolimus‐eluting stent (BES)
Number of subjects: 170
Study 33402278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SES and BES
Number of subjects: 170
Study 33402278 — intervention group
Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 170
Study 33402278 — intervention group
Group type: COMPARATOR
Intervention: BES
Number of subjects: 170
Study 32996349 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based intervention
Number of subjects: 164
Study 35635717 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR6390 150-mg tablet under high-fat conditions
Number of subjects: 24
Study 35635717 — intervention group
Group type: COMPARATOR
Intervention: SHR6390 150-mg tablet under fasting conditions
Number of subjects: 24
Study 32193541 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (tCS)
Number of subjects: 111
Study 34216470 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Number of subjects: 186
Study 34216470 — intervention group
Group type: COMPARATOR
Intervention: Cipargamin
Number of subjects: 186
Study 33960445 — intervention group
Group type: EXPERIMENTAL
Intervention: Imepitoin (30 mg/kg BID)
Number of subjects: 45
Study 33960445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 32281393 — intervention group
Group type: EXPERIMENTAL
Intervention: Major CIED infection
Number of subjects: 0
Study 33601673 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (Group A)
Number of subjects: 160
Study 33601673 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (Group B)
Number of subjects: 160
Study 32358566 — intervention group
Group type: EXPERIMENTAL
Intervention: Splicing factor mutations (SRSF2, U2AF1, SF3B1)
Number of subjects: 2678
Study 32358566 — intervention group
Group type: EXPERIMENTAL
Intervention: SRSF2(P95H) mutants
Number of subjects: 2678
Study 35708140 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 14
Study 35708140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 35169373 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement, antibiotics, irrigation and retention of prosthesis (DAIR)
Number of subjects: 70
Study 35700926 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application
Number of subjects: 86
Study 35700926 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 32149425 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site active referral (OSR)
Number of subjects: 1163
Study 32149425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile text messaging referral (TMR)
Number of subjects: 1163
Study 32149425 — intervention group
Group type: COMPARATOR
Intervention: Brief cessation advice only (control)
Number of subjects: 1163
Study 32189052 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tree analysis model based on ultrasonography and clinical findings
Number of subjects: 242
Study 32189052 — intervention group
Group type: EXPERIMENTAL
Intervention: DTA model based on categorical parameters alone
Number of subjects: 242
Study 33683799 — intervention group
Group type: EXPERIMENTAL
Intervention: IPAQ-SF
Number of subjects: 0
Study 33683799 — intervention group
Group type: EXPERIMENTAL
Intervention: PASE
Number of subjects: 0
Study 36027443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual SPC arm (perindopril/amlodipine) initial dose 4/5 mg, up titrated to 8/5 mg, 8/10 mg if needed.
Number of subjects: 440
Study 36027443 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple SPC arm (perindopril/amlodipine/indapamide) initial dose 4/5/1.25 mg, up titrated to 8/5/2.5 mg, 8/10/2.5 mg if needed.
Number of subjects: 440
Study 32572802 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg/day)
Number of subjects: 70
Study 32572802 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/day)
Number of subjects: 70
Study 36162067 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Support Psychotherapy (GSP)
Number of subjects: 1140
Study 36162067 — intervention group
Group type: COMPARATOR
Intervention: Group HIV Education (GHE)
Number of subjects: 1140
Study 34161706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 625
Study 34161706 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (1-g single dose)
Number of subjects: 625
Study 34161706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 625
Study 34161706 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 625
Study 36456992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin treatment
Number of subjects: 50
Study 36456992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33439221 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge video‐based virtual visit
Number of subjects: 432
Study 33439221 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up
Number of subjects: 432
Study 35798680 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based behavioral activation (BA) intervention
Number of subjects: 127
Study 35798680 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 127
Study 33536003 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction strategy for tobacco use
Number of subjects: 0
Study 33536003 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of food insecurity reduction strategy
Number of subjects: 0
Study 33536003 — intervention group
Group type: COMPARATOR
Intervention: Strategies addressing excess alcohol use and overcrowding
Number of subjects: 0
Study 35471613 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 30
Study 35471613 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 30
Study 35471613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 30
Study 32394654 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAO's five-needle method
Number of subjects: 210
Study 32394654 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 210
Study 33298706 — intervention group
Group type: EXPERIMENTAL
Intervention: The Coleman Care Transition Intervention adapted for ED visitors
Number of subjects: 0
Study 33298706 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 0
Study 32174482 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with 16 anterior-posterior perturbations
Number of subjects: 30
Study 32174482 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking (control group)
Number of subjects: 30
Study 33557599 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS (mHealth intervention)
Number of subjects: 0
Study 33557599 — intervention group
Group type: COMPARATOR
Intervention: WRAP (clinic-based intervention)
Number of subjects: 0
Study 35011054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional protein supplementation (NS)
Number of subjects: 600
Study 35011054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (NE)
Number of subjects: 600
Study 35011054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutritional protein supplementation and nutrition education (NS + NE)
Number of subjects: 600
Study 35011054 — intervention group
Group type: COMPARATOR
Intervention: Usual supportive care from ASHA (UC)
Number of subjects: 600
Study 35011054 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual supportive care from ASHA (UC) plus nutrition education (NE)
Number of subjects: 600
Study 35011054 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual supportive care from ASHA (UC) plus nutritional protein supplementation (NS)
Number of subjects: 600
Study 35011054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined UC plus NE plus NS
Number of subjects: 600
Study 34134825 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)‐enhanced parent‐teen behavior therapy
Number of subjects: 114
Study 33063705 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous autologous serum therapy
Number of subjects: 64
Study 33063705 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular autologous serum therapy
Number of subjects: 64
Study 36351726 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐WOMAC
Number of subjects: 70
Study 36351726 — intervention group
Group type: COMPARATOR
Intervention: p‐WOMAC
Number of subjects: 70
Study 34698397 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 474
Study 34698397 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 474
Study 32017703 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention delivered to senior nursing students
Number of subjects: 90
Study 32017703 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 90
Study 36451459 — intervention group
Group type: EXPERIMENTAL
Intervention: PN + EN (supplemental parenteral nutrition)
Number of subjects: 72
Study 36451459 — intervention group
Group type: COMPARATOR
Intervention: TEN (total enteral nutrition)
Number of subjects: 72
Study 34598737 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-group cognitive-behavioral (FGCB) preventive intervention (12 sessions)
Number of subjects: 100
Study 34598737 — intervention group
Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 100
Study 35690515 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-11 PET/CT
Number of subjects: 82
Study 35690515 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-PSMA-11 PET/CT
Number of subjects: 82
Study 35690515 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-11
Number of subjects: 82
Study 35690515 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-PSMA-11
Number of subjects: 82
Study 35690515 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-11 and 68Ga-PSMA-11
Number of subjects: 82
Study 34261523 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive remote monitoring technology
Number of subjects: 29
Study 34261523 — intervention group
Group type: COMPARATOR
Intervention: Home care services
Number of subjects: 29
Study 34261523 — intervention group
Group type: COMPARATOR
Intervention: Family/friend caregiver support
Number of subjects: 29
Study 34261523 — intervention group
Group type: COMPARATOR
Intervention: Residential long-term care homes
Number of subjects: 29
Study 32527290 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive surfactant administration (LISA)
Number of subjects: 600
Study 32527290 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal surfactant administration followed by low peak pressure ventilation (LPPSA)
Number of subjects: 600
Study 34986284 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy plus eltrombopag (Group B)
Number of subjects: 197
Study 34986284 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy (Group A)
Number of subjects: 197
Study 34554372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg o.d.)
Number of subjects: 0
Study 34554372 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5 mg o.d.)
Number of subjects: 0
Study 32462216 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination for surgical disease
Number of subjects: 780
Study 32462216 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical needs survey administered by surgeons
Number of subjects: 780
Study 32462216 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of surgical histories
Number of subjects: 780
Study 33942548 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic guidance group
Number of subjects: 30
Study 33942548 — intervention group
Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 30
Study 32046671 — intervention group
Group type: COMPARATOR
Intervention: Motor-based treatment consistent with current best practices in speech therapy (40% of participants)
Number of subjects: 110
Study 32046671 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment incorporating visual biofeedback (60% of participants)
Number of subjects: 110
Study 32046671 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual display of the acoustic signal of speech (within biofeedback condition)
Number of subjects: 110
Study 32046671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of the tongue during speech (within biofeedback condition)
Number of subjects: 110
Study 33021580 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension (LE) power
Number of subjects: 80
Study 33021580 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension (KE) torque
Number of subjects: 80
Study 33021580 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg press one repetition maximum (LP RM)
Number of subjects: 80
Study 33345312 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (CMX)
Number of subjects: 30
Study 33345312 — intervention group
Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 30
Study 33345312 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological assessment
Number of subjects: 30
Study 36174151 — intervention group
Group type: EXPERIMENTAL
Intervention: trauma‐focused expressive writing (EW)
Number of subjects: 28
Study 36174151 — intervention group
Group type: EXPERIMENTAL
Intervention: neutral expressive writing (EW)
Number of subjects: 28
Study 36174151 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 28
Study 33602279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine supplementation (2 mg)
Number of subjects: 11
Study 32727558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU oral drop daily for 5 days)
Number of subjects: 74
Study 32727558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 IU daily for 5 days)
Number of subjects: 74
Study 35306032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily
Number of subjects: 40
Study 35306032 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 40
Study 34702730 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week cognitive rehabilitation programme
Number of subjects: 75
Study 35390457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol (CBD)
Number of subjects: 80
Study 35390457 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Oil (EO)
Number of subjects: 80
Study 35390457 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol (CBD) + Essential Oil (EO)
Number of subjects: 80
Study 35390457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 80